1. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

protein kinases

" in MedChemExpress (MCE) Product Catalog:

575

Inhibitors & Agonists

15

Screening Libraries

3

Fluorescent Dye

5

Biochemical Assay Reagents

109

Peptides

1

MCE Kits

54

Natural
Products

3

Recombinant Proteins

9

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-47026

    Others Others
    Protein kinase inhibitor 6 is a protein kinase inhibitor.
    <em>Protein</em> <em>kinase</em> inhibitor 6
  • HY-100984
    HA-100
    1 Publications Verification

    PKA PKC Myosin ROCK Cancer
    HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .
    HA-100
  • HY-P3944

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent <em>Protein</em> <em>Kinase</em> Substrate
  • HY-P3943

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent <em>Protein</em> <em>Kinase</em> Substrate Analog
  • HY-100984A

    PKA PKC Myosin ROCK Cancer
    HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .
    HA-100 hydrochloride
  • HY-148066

    Others Others
    DB0662 is a compound for kinase-targeted protein degradation and can be used in studies of diseases mediated by abnormal kinase activity, as well as for the identification of degradable kinases and optimal kinases .
    DB0662
  • HY-153743

    ROS Kinase Trk Receptor Cancer
    Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively) .
    <em>Protein</em> <em>kinase</em> inhibitor 4
  • HY-108136A
    Bisindolylmaleimide X hydrochloride
    2 Publications Verification

    BIM-X hydrochloride; Ro31-8425 hydrochloride

    PKC CDK Cardiovascular Disease
    Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective protein kinase C (PKC) inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM .
    Bisindolylmaleimide X hydrochloride
  • HY-P3930

    IP20-amide

    PKA Neurological Disease
    PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a Ki of 2.3 nM .
    PKI (5-24),amide
  • HY-P1292A

    PKG Cancer
    PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM .
    PKG inhibitor peptide TFA
  • HY-15847
    HS38
    1 Publications Verification

    DAPK Cardiovascular Disease
    HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders .
    HS38
  • HY-152830A

    Others Cancer
    Adrixetinib (TFA) is an inhibitor of protein tyrosine kinase with antineoplastic activity .
    Adrixetinib TFA
  • HY-147312

    Others Cancer
    GSK-1520489A is a PKMYT1 (active protein kinase) inhibitor (IC50=115 nM, Ki=10.94 nM) .
    GSK-1520489A
  • HY-100983

    PKC Cancer
    Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .
    <em>Protein</em> <em>kinase</em> inhibitor H-7 dihydrochloride
  • HY-150617

    M4076; ATM Inhibitor-5

    ATM/ATR Cancer
    Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1) .
    Lartesertib
  • HY-105416

    UCN-1028C

    Antibiotic PKC Apoptosis Infection Cancer
    Calphostin C is a potent and specific inhibitor of protein kinase C. Calphostin C is an antitumor antibiotic. Calphostin C has 1000 times more inhibitory to protein kinase C with an IC50 of 0.05 μM than other protein kinases. Calphostin C induces apoptosis in some tumor cell lines. Calphostin C has potent cytotoxic activity and antitumor activity .
    Calphostin C
  • HY-P1289A

    PKC Others
    [Ala107]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 46-145 μM .
    [Ala107]MBP(104-118)
  • HY-P1289

    PKC Others
    [Ala113]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 28-62 μM .
    [Ala113]MBP(104-118)
  • HY-P1289C

    PKC Others
    [Ala113]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 28-62 μM .
    [Ala113]MBP(104-118) TFA
  • HY-P1289B

    PKC Others
    [Ala107]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 46-145 μM .
    [Ala107]MBP(104-118) TFA
  • HY-148763

    Casein Kinase Inflammation/Immunology Cancer
    CK2-IN-6 is a potent protein kinase CK2 inhibitor that can be used in the study of cancer as well as other kinase-related conditions, including inflammation, pain and certain immune diseases .
    CK2-IN-6
  • HY-P2673

    KRTLRR

    EGFR Others
    Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) is a hexapeptide. Lys-Arg-Thr-Leu-Arg-Arg is a substrate of protein kinase C from EGF receptor. Lys-Arg-Thr-Leu-Arg-Arg can be used to determine the activity of protein kinase C .
    Lys-Arg-Thr-Leu-Arg-Arg
  • HY-141453

    RIP kinase Cancer
    Desmethyl-WEHI-345 analog is a protein kinase inhibitor extracted from patent WO2012003544A1, example 12. Desmethyl-WEHI-345 analog can be used for the research of colon cancer .
    Desmethyl-WEHI-345 analog
  • HY-P3929

    PKA Cancer
    PKI (14-24)amide is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
    PKI (14-24)amide
  • HY-P3929A

    PKA Cancer
    PKI (14-24)amide TFA is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
    PKI (14-24)amide TFA
  • HY-153437

    RIP kinase Cancer
    RIP1 kinase inhibitor 7 (compound 41) is a potent receptor interacting protein 1 kinase (RIP1) Inhibitor with an IC50 of <100 nM for human RIP1. RIP1 kinase inhibitor 7 has an EC50 of 1-100 nM in the cell necrosis assay .
    RIP1 kinase inhibitor 7
  • HY-101290A

    Cyclin G-associated Kinase (GAK) AAK1 Neurological Disease
    BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain .
    BMT-090605 hydrochloride
  • HY-150617A

    (Rac)-M4076; (Rac)-ATM Inhibitor-5

    ATM/ATR Cancer
    (Rac)-Lartesertib ((Rac)-M4076; (Rac)-ATM Inhibitor-5) is an isoform of Lartesertib (HY-150617), which is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1) .
    (Rac)-Lartesertib
  • HY-P3784

    PKC Metabolic Disease Inflammation/Immunology Cancer
    FKKSFKL-NH2 is a protein kinase C-selective peptide. FKKSFKL-NH2 can be used for the research of various biochemical .
    FKKSFKL-NH2
  • HY-115741

    Others Neurological Disease Cancer
    3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket) .
    3BrB-PP1
  • HY-108602

    PKC Cancer
    Bryostatin 3, a macrocyclic lactone, is a protein kinase C activator, with a Ki of 2.75 nM. Bryostatin 3 can block 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibition of cell proliferation, yet did not block TPA-enhanced cell-substratum adhesion .
    Bryostatin 3
  • HY-118131

    Ser/Thr Protease Infection
    PKR-IN-C51(compound 51) is an ATP-competitive double-stranded RNA-activated protein kinase (PKR) inhibitor with an IC50 of 9 μM. PKR-IN-C51 inhibits intracellular PKR activation in a dose-dependent manner in primary mouse macrophages .
    PKR-IN-C51
  • HY-148062

    PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 Others
    RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity .
    RSS0680
  • HY-148063

    PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) ULK Wee1 LIM Kinase (LIMK) Others
    DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB0614
  • HY-145036

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .
    HPK1-IN-10
  • HY-145037

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) .
    HPK1-IN-11
  • HY-145038

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .
    HPK1-IN-12
  • HY-145039

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .
    HPK1-IN-13
  • HY-145040

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .
    HPK1-IN-14
  • HY-145035

    MAP4K Inflammation/Immunology Cancer
    HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .
    HPK1-IN-9
  • HY-148061

    PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB1113
  • HY-148382

    RIP kinase Necroptosis Neurological Disease Inflammation/Immunology
    RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC50 value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases .
    RI-962
  • HY-115930

    Bcl-2 Family Cardiovascular Disease
    Bim-IN-1 is a potent Bim expression inhibitor. Bim-IN-1 reduces Bim expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity .
    Bim-IN-1
  • HY-P1290A
    PKA Inhibitor Fragment (6-22) amide TFA
    2 Publications Verification

    PKI-(6-22)-amide TFA

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide TFA
  • HY-P1290

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide
  • HY-144301

    AAK1 Neurological Disease
    AAK1-IN-2 (compound (S)-31) is a potent, selective and brain-penetrant inhibitor of Adaptor Protein 2-Associated Kinase 1 (AAK1), with an IC50 of 5.8 nM. AAK1-IN-2 can be used for the research of neuropathic pain .
    AAK1-IN-2
  • HY-144301A

    AAK1 Neurological Disease
    AAK1-IN-2 TFA (compound (S)-31) is a potent, selective and brain-penetrant inhibitor of Adaptor Protein 2-Associated Kinase 1 (AAK1), with an IC50 of 5.8 nM. AAK1-IN-2 TFA can be used for the research of neuropathic pain .
    AAK1-IN-2 TFA
  • HY-148189
    Aldometanib
    2 Publications Verification

    LXY-05-029

    AMPK Metabolic Disease
    Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .
    Aldometanib
  • HY-13977A
    PKR-IN-C16
    2 Publications Verification

    Apoptosis Neurological Disease
    PKR-IN-C16 (Compound C16) is a specific double-stranded RNA-dependent protein kinase (PKR) inhibitor. PKR-IN-C16 shows promising neuroprotective properties and can rescue acute brain lesions .
    PKR-IN-C16
  • HY-118837

    ROCK Cancer
    WF-536 is an orally active inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK). WF-536 has tumor anti-metastatic activity. WF-536 can be used for the research of cancer .
    WF-536

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: